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The aim of this study is to clarify which signaling mechanism operates in Fc7 receptor-mediated endocytosis n human neutrophils. Endocytosis 
of immune complexes was inhibited by antibodies directed to cell membrane phospholipase C (PLC) and A 2 (PLA2) (maximal inhibition obtained 
was 57% and 28%, respectively), being almost abolished by these antibodies if used in combination (up to 91~ inhibition). The protein kinase C 
(PKC) activator, phorbol 12,13-dibutyrate, r versed this inhibitory effect. Four different PKC inhibitors (H-7, palmitoylcarnitine, sphingosine, and 
tamoxifen) produced adose-dependent i hibition of endocytosis, up to over 80% in each case. H-8 (I-10/~M) which inhibits cyclic nucleotide protein 
kinases but not PKC had no effect upon endocytosis. It is concluded that Fc~, receptor-induced activation of PLC and PLA 2 triggers endocytosis 
by activation of PKC. 
Protein kinase C; Endocytosis; Fcy receptor; Phospholipase C; Phospholipase Az; Neutrophil activation 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Neutrophil activation via the Fc3,R is a major event in 
host organism defense. The intracellular signals 
generated, which eventually produce a combination of 
two responses (receptor-mediated ndo/phagocytosis 
and the so-called 'respiratory burst' with superoxide 
production), are not elucidated and seem rather com- 
plex and intertwined. 
Several recent lines of evidence point to the multi- 
functional enzyme PKC, originally discovered by 
Nishizuka [1,2], as possibly involved in Fc3,R-mediated 
signaling [3-5], with proposed roles in triggering 
phagocytosis [6-8] and/or superoxide production 
[9-11]. However, PKC role is still unclear, the main two 
unresolved issues being (i) how important PKC activity 
is and (ii) which is(are) the pathway(s) linking the FcyR 
to PKC activation. 
The pesent study addresses these issues in the case of 
Fc3,R-triggered endocytosis in human neutrophils 
showing that (i) PKC activation is crucial to triggering 
endocytosis and (ii) there are (at least) two different 
pathways of PKC activation starting from the Fc3,R, 
through activation of cell-membrane PLC and PLA2. 
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2.1. Cells 
Human neutrophils were isolated as follows: after separating 
monocytes and lymphocytes out of fresh blood samples from healthy 
volunteers (anti-HIV and HBsAg negative) as previously described 
[12], the resulting pellet was gently mixed with a double volume of 
PBS containing 0.62507o polyvinylacetate and 0.207o gelatin (freshly 
prepared). After 75 min incubation (37°C, 10007o humidity, 1007o 
CO2) in vertical cylinders, polymorphonuclear cells were harvested 
from the erythrocyte-free supernatant and washed three times. 
2.2. Immune complexes 
Two different radiolabeled immune complexes were prepared in 
vitro (1 h at 37°C incubation of antigen and antibody in PBS contain- 
ing 0.2°70 gelatin; antigen at 5 #g/ml), using [~251]BSA with rabbit IgG 
anti-BSA and [125I]IgM (human, affinity-purified, polyclonal) with 
rabbit IgG anti-lgM. Radioactive labeling of the antigen was done ac- 
cording to Regoeczi [13] to yield a specific activity of 3.5-4.5 x 108 
cpm/mg protein. 
2.3. Anti-phospholipase ntibodies 
Monospecific anti-phospholipase C and A2 antibodies (F(ab')2 
fragment of the IgG molecule) were prepared as previously described 
[12,14]. The antibodies dose-dependently inhibit the respective n- 
zymes in living cells [12,14-17]. 
2.4. Endocytosis a say 
Cells (0.2-1.0 x 107/ml) were incubated in culture medium (RPMI 
1640, Flow Laboratories) containing various concentrations of PKC 
inhibitors or of anti-phospholipase antibodies, for 15 rain or 1 h, 
respectively. After adding the immune complexes (at a final 3 x l05 
cpm/ml) for 15 min at 37°C and washing, cells were resuspended for 
10 min in 20 mM HCI (pH 1.7) to dissociate membrane-bound im- 
mune complexes, which were not internalised. After two washings, 
cellular radioactivity was measured. All operations after the incuba- 
tion with immune complexes were performed at 0°C. Cells not expos- 
ed to drugs and incubated with the radiolabeled antigens instead of 
the immune complexes were used as a control for nonspecific inter- 
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nalisation and the counts were subtracted from all other readings. 
Cells incubated with the immune complexes but not exposed to drugs 
were used as an endocytosis control and results were expressed as 
percentage r ferred to this control taken as 100%. 
3. RESULTS 
Neutrophil endocytosis of our in vitro-prepared IgG- 
coated immune complexes normally occurred at a high 
rate: at 15 rain actually all the cell-bound radiolabeled 
ligand was internalised, leaving less than 5°-/o exposed 
on the cell surface. Both types of immune complexes 
were used in all experiments and no significant dif- 
ferences were noted. 
The internalisation rate was significantly reduced by 
the four different PKC inhibitors: sphingosine, pal- 
mitoylcarnitine, tamoxifen and H-7 (Fig. 1). At the 
concentrations used, the first two drugs did affect 
neither receptor-ligand binding nor cell viability. 
Tamoxifen showed toxic effects above 200 #M (viability 
50% only at 250 #M tamoxifen) and H-7 appeared to in- 
terfere with binding to the Fc-yR above 15 #M (total 
bound radioactivity about 50% of control at 25 #M 
H-7). 
Anti-PLC and anti-PLA2 antibodies also inhibited 
endocytosis, having a powerful additive inhibitory ef- 
fect if used in combination (Fig. 2A). This inhibition 
was reversed by the PKC activator phorbol 12,13- 
dibutyrate (100 nM) (Fig. 2B). Non-immune IgG, used 
in similar concentrations, a  a specificity control for the 
antibodies, had no effect upon endocytosis. 
H-8 did not show any effect upon endocytosis atcon- 
centrations up to 10 #M at which it inhibits cyclic 
nucleotide-dependent pro ein kinases but not PKC. 
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Fig. 2. (A) Maximal inhibition of endocytosis obtained with anti-PLC 
and anti-PLA2 antibodies used alone or in combination. (B) Reversal 
of the antibody-induced inhibition by 100 nM phorbol 
12,13-dibutyrate. Blank bars are specificity controls using non- 
immune lgG instead of the antibodies. Maximal inhibition was deter- 
mined at excess antibody concentration (100 /~g/106 ceils). 
Means + SD of 4 separate xperiments. 
4. DISCUSSION 
The dose-dependent, up to over 80% inhibition of 
endocytosis by four different drugs which share only 
the quality of being PKC inhibitors [18-21], strongly 
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Fig. 1. Inhibition of endocytosis induced by the PKC inhibitors H-7, tamoxifen, palmitoylcarnitine and sphingosine. Means +_ SD of 6 separate 
experiments. 
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suggests hat PKC activation isa necessary event in trig- 
gering FcyR-mediated endocytosis n human neutro- 
phils. Similar experiments indicate that PKC may as 
well be involved in other eceptor-mediated en ocytosis 
like enveloped virus internalization (S.N. Constan- 
tinescu, C. Cernescu, F. Balt~ and L.M. Popescu 'Pro- 
tein kinase C and viral infectivity', submitted). 
PLC-type hydrolysis and phosphoinositides as well as 
activation of PLA2 were shown to be triggered by the 
neutrophil Fc-rR [3,8]. Both could lead to PKC activa- 
tion [2,22]. Our results with specific anti-PLC and anti- 
PLA2 antibodies, which bind to and inhibit the cell- 
membrane nzymes [12,14-17], suggest an important 
cooperative involvement of PLC and PLA2 activity in 
triggering endocytosis. The endocytosis nhibition in- 
duced by PLC and PLA2 blockade is probably due to 
the failure of subsequent PKC activation because this 
inhibition is reversed if the assay medium contains the 
direct PKC activator phorbol 12,13-dibutyrate. PLC- 
dependent inositolphosphate-induced alcium tran- 
sients [22] seem to play no significant role in this case of 
receptor-mediated ndocytosis, although neutrophil 
Fc3~R-mediated phagocytosis was shown to have some 
calcium requirements [10]. 
In order to test any possible contribution from cyclic 
nucleotide signaling in triggering endocytosis, we used 
1-10 #M H-8, selectively inhibiting cAMP- and cGMP- 
dependent protein kinases (Ki for A kinase, G kinase 
and PKC of 1.2, 0.48 and 15 #M, respectively [19]). Ap- 
parently, the lack of effect upon endocytosis shows that 
cyclic nucleotides are not positively involved in this type 
of Fc3,R signaling; moreover, cAMP-dependent protein 
kinase may negatively modulate Fc3,R-mediated 
phagocytosis [9]. 
In conclusion, our results suggest that PKC activa- 
tion plays the major role in controlling Fc3,R-mediated 
endocytosis in human neutrophils. Two synergistic 
pathways appear to link the Fc3,R to PKC, through ac- 
tivation of membrane PLC and PLA2, respectively. 
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